SoftOx Solutions AS — Capital/Financing Update 2021

Mar 3, 2021

SoftOx Solutions AS: Preliminary result of the Subsequent Offering

SoftOx Solutions AS: Preliminary result of the Subsequent Offering

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the "Company") on 16 February 2021 regarding the commencement of the subscription period in the subsequent offering of up to 181,818 new shares at a subscription price of NOK 55 per offer share directed towards eligible shareholders as of 16 December 2020 (as registered in the VPS on 18 December 2020) who did not participate in the private placement successfully completed on the 16 December 2020 (the "Subsequent Offering").

The subscription period for the Subsequent Offering expired at 16:30 hours (CEST) today, 3 March 2021. Preliminary counting indicates that the Company has received subscriptions for approximately 971 404 offer shares.

The final allocation of the offer shares is expected to take place on or about 4 March 2021, in accordance with the allocation criteria set out in the national prospectus.

The final results of the Subsequent Offering will be published shortly after allocation, and letters with allocation information including subscription amount to be paid by each subscriber are expected to be distributed during the course of 4 March 2021.

The payment date for the offer shares allocated in the Subsequent Offering is 8 March 2021, and the delivery date for such shares is expected to be on or about 15 March 2021. The offer shares allocated in the Subsequent Offering are expected to be tradeable on Euronext Growth Oslo on or about 16 March 2021.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has acted as legal advisor to as the Company in connection with the Subsequent Offering.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or

Kristine Rød, FM of SoftOx Solutions AS

Mail: ir@soft-ox.com

Mobile: +47 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com